308 related articles for article (PubMed ID: 25172241)
1. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review.
Danieli MG; Gelardi C; Pedini V; Moretti R; Gabrielli A; Logullo F
Autoimmun Rev; 2014 Dec; 13(12):1182-8. PubMed ID: 25172241
[TBL] [Abstract][Full Text] [Related]
2. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.
Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K
Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases.
Chen Y; Wang C; Xu F; Ming F; Zhang H
Clin Ther; 2019 Oct; 41(10):2112-2136. PubMed ID: 31445679
[TBL] [Abstract][Full Text] [Related]
4. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use.
Gandiga PC; Ghetie D; Anderson E; Aggrawal R
Curr Rheumatol Rep; 2023 Aug; 25(8):152-168. PubMed ID: 37261663
[TBL] [Abstract][Full Text] [Related]
5. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases.
Cherin P; Belizna C; Cartry O; Lascu-Dubos G; de Jaeger C; Delain JC; Crave JC; Hachulla E
Autoimmun Rev; 2016 Mar; 15(3):281-6. PubMed ID: 26688441
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.
Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC
Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648
[TBL] [Abstract][Full Text] [Related]
7. IgPro20, the Polyneuropathy and Treatment with Hizentra
Berger M; Harbo T; Cornblath DR; Mielke O
Immunotherapy; 2018 Aug; 10(11):919-933. PubMed ID: 29764262
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R
Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.
Goyal NA; Karam C; Sheikh KA; Dimachkie MM
Muscle Nerve; 2021 Sep; 64(3):243-254. PubMed ID: 34260074
[TBL] [Abstract][Full Text] [Related]
11. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Markvardsen LH; Christiansen I; Jakobsen J
Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
[TBL] [Abstract][Full Text] [Related]
12. Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.
Danieli MG; Verga JU; Mezzanotte C; Terrenato I; Svegliati S; Bilo MB; Moroncini G
Front Immunol; 2021; 12():805705. PubMed ID: 35111165
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?
Sanchez-Ramon S; Corbi AL; Fidalgo AG; Dominguez-Soto A
Curr Pharm Des; 2016; 22(41):6300-6305. PubMed ID: 27587200
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
16. A machine learning analysis to predict the response to intravenous and subcutaneous immunoglobulin in inflammatory myopathies. A proposal for a future multi-omics approach in autoimmune diseases.
Danieli MG; Tonacci A; Paladini A; Longhi E; Moroncini G; Allegra A; Sansone F; Gangemi S
Autoimmun Rev; 2022 Jun; 21(6):103105. PubMed ID: 35452850
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin treatment in peripheral nerve disorders--indications, mechanisms of action and side-effects.
Hahn AF
Curr Opin Neurol; 2000 Oct; 13(5):575-82. PubMed ID: 11073366
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin Treatment in Neuromuscular Medicine.
Burakgazi AZ
J Clin Neuromuscul Dis; 2019 Jun; 20(4):182-193. PubMed ID: 31135621
[TBL] [Abstract][Full Text] [Related]
19. Intravenous and subcutaneous immunoglobulin G replacement therapy.
Bonilla FA
Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296
[TBL] [Abstract][Full Text] [Related]
20. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies.
Anh-Tu Hoa S; Hudson M
Semin Arthritis Rheum; 2017 Feb; 46(4):488-508. PubMed ID: 27908534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
